Prescient receives $3.4 million R&D Tax Incentive refund Key Highlights: • Prescient Therapeutics (ASX:PTX) has received a cash refund of $3.4 million under the Australian Government's R&D Tax Incentive for the financial year ended 30 June 2026 • The non-dilutive refund adds to the $6 million...
Prescient receives $3.4 million R&D Tax Refund
Filed with ASX · · 3 pages · English
Summary by 6ix AI
Prescient Therapeutics Limited has announced the receipt of a cash refund from the Australian Taxation Office under the R&D Tax Incentive program, which supports research and development activities. This funding follows a recent capital raise aimed at advancing the company's clinical studies.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Release
Prescient Therapeutics Limited on 6ix
Earlier from Prescient Therapeutics
- Notification of cessation of securities - PTX
- Change of Company Secretary
- Results of Annual General Meeting
- Chair Address and CEO AGM Presentation
- September 2026 Quarterly Update and Appendix 4C
Follow Prescient Therapeutics into a list and get an email when it puts out news.
Follow Prescient Therapeutics